SATO VICKI L 4

What Happened
Vicki L. Sato, a director of Vir Biotechnology (VIR), sold a total of 22,000 shares on March 2, 2026 in open-market transactions for aggregate proceeds of about $209,181. The filing reports two sale groupings: 21,800 shares (reported weighted average $9.50; proceeds $207,185) and 200 shares (reported weighted average $9.98; proceeds $1,996). All sales are reported as dispositions (code S).

Key Details

• Transaction date: March 2, 2026; Form 4 filed March 3, 2026 (timely filing).
• Sale breakdown:
  • 21,800 shares, reported weighted avg price $9.50, proceeds $207,185; per-footnote prices ranged from $8.97 to $9.91.
  • 200 shares, reported weighted avg price $9.98, proceeds $1,996; per-footnote prices ranged from $9.97 to $9.99.
• Total sold: 22,000 shares for approximately $209,181.
• Footnote: Sales were effected under a Rule 10b5-1 trading plan adopted March 27, 2025. Reporting person will provide per-price breakdowns on request (per filing footnotes).
• Shares owned after transaction: not specified in the details provided.
• Transaction code: S = Sale (open market/private sale).

Context
A Rule 10b5-1 plan indicates these sales were pre-arranged under an automated trading plan adopted previously (March 27, 2025) and are often used to execute routine dispositions rather than signal a change in insider view; the filing itself is factual and does not state motivations. Retail investors should view routine director sales differently from purchases, which can sometimes be a clearer signal of insider confidence.